WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced a major milestone in its global efforts to help identify newborns at risk for genetic disorders. The Company has determined that its neonatal screening technology, utilized in laboratories worldwide for more than 20 years, has helped to identify the 100,000th infant at risk for potentially life-threatening diseases, such as Phenylketonuria (PKU), which can have a positive outcome when intervention begins within the first 24 to 36 hours of life.
